Back to today’s briefing

Story perspectives

Genetic Marker HG-T: Major Barrier for Melanoma Treatment

6/6/2025

23 4

Summary

Story summary

Patients with metastatic melanoma who carry mitochondrial haplogroup T (HG-T) face a daunting challenge, as researchers at NYU Langone Health found they are 3.46 times less likely to respond to immune checkpoint inhibitors. This groundbreaking study of 1,225 patients highlights HG-T as a crucial genetic marker, paving the way for more tailored cancer treatments.

1 of 1

Story summary

Patients with metastatic melanoma who carry mitochondrial haplogroup T (HG-T) face a daunting challenge, as researchers at NYU Langone Health found they are 3.46 times less likely to respond to immune checkpoint inhibitors. This groundbreaking study of 1,225 patients highlights HG-T as a crucial genetic marker, paving the way for more tailored cancer treatments.